FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1471-1472 April 5, 2007 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Geyer, C. E.

To the Editor: In the trial reported by Geyer et al. (Dec. 28 issue),¹ which compared capecitabine alone with a combination of lapatinib and capecitabine in women with HER2-positive advanced breast cancer, approximately 60% of patients had received trastuzumab within the previous 8 weeks. It is possible that the activity of lapatinib was enhanced by the persistence of trastuzumab levels in blood. Earlier studies of the pharmacokinetics of trastuzumab administered weekly or every 3 weeks indicate that the drug's half-life is 3 to 4 weeks, although this may be an underestimate. Therefore, synergism between lapatinib and trastuzumab, leading to a . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.